Eloxx Pharmaceuticals, Inc.
ELOXNext catalyst
Exaluren
Alport Syndrome, X-Linked
Get an email about ELOX's next catalysts
Track Eloxx Pharmaceuticals (ELOX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
ELOX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
Exaluren Phase 2 Est. Readout
Estimated primary completion for Exaluren trial (NCT07523581) in Alport Syndrome, X-Linked. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Eloxx Pharmaceuticals, Inc.'s drug pipeline?β
CatalystAlert tracks 3 drug candidates in Eloxx Pharmaceuticals, Inc.'s (ELOX) pipeline across Phase 2. Its lead program is Exaluren (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Eloxx Pharmaceuticals, Inc.'s next FDA catalyst?β
Eloxx Pharmaceuticals, Inc.'s (ELOX) next tracked catalyst is a Phase 2 readout expected Q2 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ELOX biotech catalysts?β
Add ELOX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Eloxx Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
